Clinical Trial

Phase I Study of HXN6005 in Adult Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants. Researchers will compare HXN6005 to a placebo (a look-alike substance that contains no drug). Participants will take a single dose of HXN6005 or placebo on Day 1, and visit the clinic for followup and tests per the protocol scheme.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-25
notable Enrollment reduced: 40 -> 32 participants 2026-04-25
Trial Details
NCT Number NCT07449741
Lead Sponsor Helixon Biotechnology (Suzhou) Co., Ltd
Conditions Healthy Volunteers (HV)
Enrollment 32 participants
Start Date 2026-04-27
Primary Completion 2027-03-13 (estimated)
Study Completion 2027-03-13 (estimated)
Updated on ClinicalTrials.gov 2026-04-24